世茂股份(600823.SH):7.10億元酒店資產支持專項計劃資產支持證券掛牌轉讓獲上交所無異議函
格隆匯12月1日丨世茂股份(600823.SH)公佈,近日,公司收到專項計劃管理人中信信託有限責任公司轉發的上上交所出具編號為"上證函[2019]2146號"的《關於對中信信託-南京世茂希爾頓酒店資產支持專項計劃資產支持證券掛牌轉讓無異議的函》,載明由中信信託有限責任公司報送的《中信信託-南京世茂希爾頓酒店資產支持專項計劃資產支持證券掛牌轉讓申請書》及相關材料收悉。根據有關規定,中信信託-南京世茂希爾頓酒店資產支持專項計劃資產支持證券符合上交所的掛牌轉讓條件,上交所對其掛牌轉讓無異議。發行總額不超過7.10億元,無異議函自出具之日起12個月內有效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.